Clinuvel Pharmaceuticals Ltd.

Australian biopharma Clinuvel develops SCENESSE, a photoprotective drug for erythropoietic protoporphyria, and a pipeline of melanocortin‑based therapies, targeting rare genetic and metabolic disorders worldwide.

Headquarters: Australia (AUS)

Clinuvel Pharmaceuticals Ltd. Logo
Company Profile
  • HQ: Melbourne
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
CUV Clinuvel Pharmaceuticals Ltd.
Cap: 0.6B | P/E: 16.9
EQUITY ASX AUD AU000000CUV3 Active
📈
Home Login